RxDoctor Payments Data

Shubha Bhat, MD

Family Medicine · Richardson, TXNPI 1518170380

Payments from drug & device makers

$2,297in general payments, 2019–2025

Across 56 payments — averaging $41.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$1K
  • Novo Nordisk$219
  • Lilly USA, LLC$134
  • Exact Sciences$111
  • AstraZeneca$101
  • Medtronic$84
  • plus $449 from 12 others

What the payments were for

  • Speaking & faculty fees$1,20052%
  • Food & beverage$1,08647%
  • Education$121%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,297 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$123,346
Medicare patients
232
Services billed
2,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$87,981
MounjaroTirzepatide34$45,654
TradjentaLinagliptin29$35,456
JanuviaSitagliptin Phosphate17$15,417
VeozahFezolinetant12$6,543
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$6,083
SynthroidLevothyroxine Sodium51$4,775
Levothyroxine Sodium317$3,300
Gabapentin121$3,269
Atorvastatin Calcium337$2,984
Rosuvastatin Calcium150$1,965
Duloxetine Hcl71$1,909
Omeprazole139$1,781
Estradiol35$1,680
Pravastatin Sodium120$1,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$219$87,98166 claims
Lilly USA, LLCMounjaro$134$45,65434 claims
Boehringer IngelheimTradjenta$48$35,45629 claims
Astellas Pharma US IncVeozah$35$6,54312 claims
AbbVieSynthroid$58$4,77551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →